Recce Pharmaceuticals Ltd. AI Stock Analysis
Want to see AU:RCE full AI Analyst Report?
Recce Pharmaceuticals Ltd. (RCE) AI Stock Analysis
Recce Pharmaceuticals Ltd.
(ASX:RCE)
The overall score is severely depressed by the company's dire financial state, which borders on insolvency with zero revenue and deeply negative equity. While short-term technicals show some positive momentum, this is overshadowed by the fundamental risk of business failure. The negative P/E ratio further confirms the lack of earnings power.
Recce Pharmaceuticals Ltd. (RCE) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 114.69M
- Dividend Yield
- ―
- Average Volume (3M)
- 260.00K
- Price to Earnings (P/E)
- -7.1
- Beta (1Y)
- 1.19
- Revenue Growth
- ―
- EPS Growth
- 42.51%
- Country
- Australia
- Employees
- 8
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Recce Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's fo...
Recce Pharmaceuticals Ltd. Financial Statement Overview
Summary
Financial health is critically poor. Revenue has collapsed to zero, net losses exceed $10M annually, and stockholders' equity is deeply negative at -$16.7M. The company is technically insolvent with a severe cash burn of $9.9M and no clear path to fund operations.
Income Statement
8Very NegativeBalance Sheet
5Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 7.51M | 5.03M | 4.37M | 3.08M |
| Gross Profit | -356.40K | -356.40K | -2.94M | -2.19M | 4.15M | 2.90M |
| EBITDA | -22.35M | -22.81M | -20.05M | -21.35M | -16.99M | -13.87M |
| Net Income | -14.96M | -14.96M | -21.43M | -17.66M | -13.08M | -10.99M |
Balance Sheet | ||||||
| Total Assets | 8.53M | 8.53M | 12.41M | 6.37M | 2.56M | 12.62M |
| Cash, Cash Equivalents and Short-Term Investments | 2.69M | 2.69M | 10.45M | 4.42M | 1.56M | 11.58M |
| Total Debt | 10.44M | 10.44M | 10.77M | 811.19K | 250.57K | 74.76K |
| Total Liabilities | 25.25M | 25.25M | 15.47M | 15.89M | 5.14M | 2.56M |
| Stockholders Equity | -16.72M | -16.72M | -3.05M | -9.52M | -2.59M | 10.06M |
Cash Flow | ||||||
| Free Cash Flow | -9.95M | -9.95M | -20.47M | -13.15M | -12.73M | -9.05M |
| Operating Cash Flow | -9.89M | -9.89M | -20.44M | -13.01M | -12.69M | -9.01M |
| Investing Cash Flow | 123.60K | 123.60K | -443.90K | -141.90K | -38.63K | -40.34K |
| Financing Cash Flow | 2.01M | 2.01M | 26.92M | 16.00M | 2.71M | -240.50K |
Recce Pharmaceuticals Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RCE, the sentiment is Positive. The current price of 0.37 is above the 20-day moving average (MA) of 0.34, above the 50-day MA of 0.33, and below the 200-day MA of 0.43, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 61.50 is Neutral, neither overbought nor oversold. The STOCH value of 93.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:RCE.
Recce Pharmaceuticals Ltd. Peers Comparison
Overall Rating
AU:BIO63Neutral
AU:RCE46Neutral
AU:IMC45Neutral
AU:BIT43Neutral
AU:SPL43Neutral
AU:BOT38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 63Neutral | AUD 83.31M | 22.36 | 46.74% | ― | 29.68% | 1520.00% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | AUD 113.19M | -7.14 | 84.67% | ― | ― | 42.51% | |
| 45Neutral | AUD 11.95M | -2.87 | -31.88% | ― | 5.85% | 45.13% | |
| 43Neutral | AUD 5.57M | -3.56 | -54.03% | ― | ― | -100.00% | |
| 43Neutral | AUD 202.82M | -24.56 | -42.35% | ― | 145.32% | 25.75% | |
| 38Underperform | AUD 22.10M | -0.25 | -118.74% | ― | 499.47% | 31.20% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:RCE | Recce Pharmaceuticals Ltd. | 0.37 | -0.07 | -14.94% | |
| AU:BIT | Biotron Limited | ― | ― | ― | |
| AU:SPL | Starpharma Holdings Limited | 0.42 | 0.01 | 2.69% | |
| AU:IMC | Immuron Limited | 0.04 | -0.03 | -41.27% | |
| AU:BOT | Botanix Pharmaceuticals Limited | 0.01 | -0.12 | -92.00% | |
| AU:BIO | Biome Australia Ltd | 0.36 | -0.07 | -16.28% |
Recce Pharmaceuticals Ltd. Corporate Events
Recce Pharmaceuticals Issues New Shares in Compliant Capital Move
Recce Pharmaceuticals Ltd. has issued 74,021 fully paid ordinary shares, advising that the issuance was conducted without a disclosure document under the relevant fundraising provisions of the Corporations Act. The company confirmed it is compliant w...
Recce Pharmaceuticals Seeks ASX Quotation for New Employee Incentive Shares
Recce Pharmaceuticals Ltd has applied to the ASX for quotation of 74,021 new ordinary fully paid shares issued under an employee incentive scheme. The new securities, to be quoted from 30 October 2026, modestly increase the company’s free-float and r...
Recce strengthens Phase 3 DFI program and expands anti-infective IP in Vietnam
Recce reported Q1 FY2027 operational progress, highlighted by ethics approval for an amended pivotal Phase 3 trial of RECCE 327 Topical Gel in diabetic foot infections in Australia. The new randomised, active-controlled non-inferiority design against...
Recce and Arrotex Strike Exclusive Deal for Diabetic Foot Infection Gel
Recce Pharmaceuticals and Arrotex Pharmaceuticals have signed an exclusive license and commercialization agreement for Arrotex to register and market RECCE 327 topical gel for diabetic foot infections in Australia and New Zealand. Recce will retain e...
Recce Faces Key DMC Review as Phase 3 Diabetic Foot Gel Trial Shows Strong Signals
Recce Pharmaceuticals reported that blinded data from its pivotal Phase 3 trial of RECCE 327 Gel for diabetic foot infections in Indonesia show strong efficacy signals and an excellent safety and tolerability profile. The study has enrolled 90 patien...
Recce Pharmaceuticals Sets 2026 AGM as Synthetic Anti-Infective Pipeline Gains Recognition
Recce Pharmaceuticals has dispatched materials for its 2026 Annual General Meeting to shareholders, including the formal notice, proxy form and an access letter, ahead of the meeting scheduled for 6 November 2026 in Sydney with a concurrent virtual o...
Recce Pharmaceuticals Reports Lapse of Conditional Options
Recce Pharmaceuticals has notified the market of the cessation of 114,999 RCEAO options, which were due to expire on 07 November 2029 at an exercise price of $0.56. The options have lapsed following the failure or impossibility of satisfying the cond...
Recce Pharmaceuticals faces shareholder push for governance changes and board shake-up
Recce Pharmaceuticals has received a shareholder notice under Australian corporations law proposing governance changes and an independent review of its strategy. The notice, submitted by substantial shareholder Gavin Brown, seeks to amend the company...
Recce Sets 2026 AGM Date as It Advances Synthetic Anti-Infective Pipeline
Recce Pharmaceuticals has scheduled its 2026 Annual General Meeting for 6 November 2026 in Sydney and set 25 September 2026 as the deadline for director nominations, signaling ongoing corporate governance processes and board planning. The meeting tim...
Recce Investors Reject Option Issues and Placement Ratification at General Meeting
Recce Pharmaceuticals reported the results of its general meeting in Sydney, where all resolutions were conducted by poll and several key proposals failed to secure shareholder approval. The most significant rejection concerned the proposed issue of...
Recce Pharmaceuticals Issues Investor Presentation with Extensive Legal Disclaimers
Recce Pharmaceuticals has released a general meeting presentation that emphasises extensive legal and investment disclaimers, cautioning prospective investors not to treat its materials as financial, legal or tax advice and to undertake their own ind...
Recce Pharmaceuticals Files ASX Corporate Governance Statement and Appendix 4G
Recce Pharmaceuticals has lodged its corporate governance statement for the year ended 30 June 2026 as part of its annual report, confirming compliance with ASX Listing Rule requirements. The statement, current as at 31 August 2026 and approved by th...
Recce Pharmaceuticals Narrows Loss as Global Anti-Infective Programs Advance
Recce Pharmaceuticals reported a narrower net loss for the year to 30 June 2026, reflecting continued investment in its anti-infective portfolio while remaining pre-revenue. The company advanced its lead candidate R327G into patient dosing in a regis...
Recce wins Australian approval to expand pivotal Phase 3 diabetic foot trial
Recce Pharmaceuticals has secured approval from an Australian Human Research Ethics Committee for a key amendment to its pivotal Phase 3 trial of RECCE 327 Topical Gel in diabetic foot infections. The change adds a randomized, active-controlled, non-...
Recce Director Lifts Stake via Share Purchase Plan
Recce Pharmaceuticals disclosed a change in director Dr John Prendergast’s holdings following his participation in the company’s recent share purchase plan. Prendergast acquired 37,500 fully paid ordinary shares at $0.40 each, increasing his direct s...
Recce Pharmaceuticals Issues 250,000 New Shares Under Corporations Act Exemption
Recce Pharmaceuticals has issued 250,000 fully paid ordinary shares on 31 July 2026 and notified the market that this capital raising was conducted without a prospectus under the exemption provisions of the Corporations Act. The company confirmed it...
Recce Pharmaceuticals Seeks ASX Quotation for Advisory Fee Shares
Recce Pharmaceuticals Ltd., an Australian biotech company listed on the ASX as RCE, operates in the pharmaceutical and life sciences sector. It develops medical therapies and uses a mix of cash and equity-based compensation to engage corporate adviso...
Recce Raises A$6.4m via Placement and Share Purchase Plan, Adds Layered Option Incentives
Recce Pharmaceuticals has completed its Share Purchase Plan, raising approximately A$2.4 million from shareholders, alongside a previously completed A$4.0 million institutional placement. The combined Offer has delivered total proceeds of A$6.4 milli...
Recce Pharmaceuticals Seeks ASX Quotation for Over 6 Million New Shares
Recce Pharmaceuticals Ltd has applied for quotation of 6,051,250 new ordinary fully paid shares on the ASX, designated under the code RCE, with an issue date of 31 July 2026. The securities are being brought to market through a standard Appendix 2A a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026
